Skip to content
Search

Latest Stories

Covid-19 vaccine to be offered to all children aged five to 11 in England from April

All children aged five to 11 in England will be offered a Covid-19 vaccine, the government said on Wednesday (February 16) -- following similar announcements in the rest of the UK.

Asked what role community pharmacy was expected be play in the rollout, a department of Heath and Social Care spokesperson told Pharmacy Business: “The NHS is working on updated operational guidance and will set out how this is going to be rolled out in due course.”


The move, coming nearly two months after British regulators approved Pfizer and BioNTech's shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries.

It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective".

However, health secretary Sajid Javid -- who has responsibility for England only -- said he had now accepted guidance from the Joint Committee on Vaccination and Immunization, which advises UK health departments, to expand the rollout.

"The NHS will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

Javid added the priority remained offering vaccines and boosters to adults and vulnerable youngsters, noting that children without underlying health conditions are at low risk of serious illness from coronavirus.

Hours earlier, first minister Nicola Sturgeon announced that Scotland would also start jabbing five to 11-year-olds, while Wales unveiled the same policy on Tuesday.

Northern Ireland also followed suit on Wednesday.

The US was the first large country to begin jabbing under-12s in November and said last month it had so far vaccinated more than eight million of them.

Pfizer and BioNTech announced earlier this month that they are seeking emergency authorization from US health regulators for use of their jab for children aged over six months and under five years.

Meanwhile the European Union's medicines watchdog approved the firms' shot for five to 11-year-olds in November, and several EU nations started vaccinating them the following month.

Other countries around the world, including Israel, China, Argentina, have also begun jabbing the age group.

However, some nations such as Sweden have opted against the move, continuing to recommend jabs only for at-risk children.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less